Fig. 3.

a Effects of Nesfatin-1 before and after treatment with PTx (10 pmol/L), Anantin (100 nmol/L), PD (100 nmol/L), KT5823 (100 nmol/L), and EHNA (100 nmol/L) on LVP, +(LVdP/dt)_max, −(LVdP/dt)_max, in the isolated and Langendorff-perfused rat heart. b cGMP concentrations in control and Nesfatin-1-treated heart extracts. c Immunoblots of pERK1/2, ERK total, pAKT, and AKT total in control and Nesfatin-1-treated hearts (cardiac homogenates). d Nesfatin-1 co-immunoprecipitation with NPR-A. Percentage changes were evaluated as mean ± SE of six experiments for each group. Significant difference (one-way ANOVA) from control values of Nesfatin-1 versus Krebs–Henseleit solution (KHs), *p < 0.05. Comparison between groups treated with Nesfatin-1 alone versus antagonist, ^§ p < 0.05